Management of pegylated interferon alpha toxicity in adjuvant therapy of melanoma

Expert Opinion on Biological Therapy

Volumn 12, Issue 8, 2012, Pages 1087-1099

  Daud, Adil ^a   Soon, Christopher ^a   Dummer, Reinhard ^b   Eggermont, Alexander Mm ^c   Hwu, Wen Jen ^d   Grob, Jean Jacques ^e   Garbe, Claus ^f   Hauschild, Axel ^g  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e TIMONE HOSPITAL   (France)

^f UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^g UNIVERSITY OF KIEL   (Germany)

Author keywords

adjuvant therapy; drug therapy management; IFN 2b; melanoma; PegIFN 2b; toxicity

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; ANTIDEPRESSANT AGENT; BUTALBITAL PLUS CAFFEINE PLUS PARACETAMOL; DRONABINOL; FIBRIC ACID DERIVATIVE; IBUPROFEN; ONDANSETRON; PARACETAMOL; PEGINTERFERON ALPHA2B; PROCHLORPERAZINE; STEROID;

ADJUVANT THERAPY; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANOREXIA; APPETITE DISORDER; ARTHRALGIA; BLOOD TOXICITY; BLURRED VISION; BONE MARROW SUPPRESSION; CHILL; COGNITIVE THERAPY; COUGHING; DEPRESSION; DIARRHEA; DIZZINESS; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEVER; HEADACHE; HEART ATRIUM FIBRILLATION; HEPATITIS C; HUMAN; HUMIDIFIER; HYPERTRIGLYCERIDEMIA; INJECTION SITE REACTION; INSOMNIA; KIDNEY CARCINOMA; KIDNEY CLEARANCE; LEG FRACTURE; LEUKOPENIA; LIFESTYLE MODIFICATION; LIVER TOXICITY; LOW DRUG DOSE; MELANOMA; META ANALYSIS (TOPIC); METASTASIS FREE SURVIVAL; MYALGIA; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; NEUTROPHIL COUNT; NONHUMAN; OVERALL SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RECURRENCE FREE SURVIVAL; RETINA MACULA EDEMA; RETINOPATHY; REVIEW; RIGOR; SIDE EFFECT; SKIN MANIFESTATION; STAPHYLOCOCCUS INFECTION; SUPRAVENTRICULAR TACHYCARDIA; TASTE DISORDER; VISUAL ACUITY; VOMITING;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INTERFERON-ALPHA; MELANOMA; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 84863793064     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2012.694421     Document Type: Review

References (26)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics. CA Cancer J Clin 2012;62(1):10-29
2. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009;27(36):6199-206
3. Kirkwood JM, Dreno B, Hauschild A, et al. DERMA phase III trial of MAGE-A3 antigen-specific cancer immunotherapeutic (ASCI) as adjuvant therapy in patients with MAGE-A3-positive resected stage III melanoma. J Clin Oncol 2011;29(Suppl):abstract TPS232
4. Davar D, Tarhini A, Kirkwood JM. Adjuvant therapy: Melanoma. J Skin Cancer 2011;2011:274382
5. Mocellin S, Pasquali S, Rossi CR, Nitti D. Interferon alpha adjuvant therapy in patients with high-risk melanoma: A systematic review and meta-analysis. J Natl Cancer Inst 2010;102(7):493-501
6. Kirkwood JM, Strawderman MH, Ernstoff MS, et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The eastern cooperative oncology group trial EST 1684. J Clin Oncol 1996;14(1):7-17
7. Kirkwood JM, Ibrahim JG, Sondak VK, et al. High- and low-dose interferon alfa-2b in high-risk melanoma: First analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 2000;18(12):2444-58
8. Kirkwood JM, Ibrahim JG, Sosman JA, et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: Results of intergroup trial E1694/S9512/C509801. J Clin Oncol 2001;19(9):2370-80
9. Tannir NM, Cohen L,Wang X, et al. Improved tolerability and quality of life with maintained efficacy using twice-daily low-dose interferon-alpha-2b: Results of a randomized phase II trial of low-dose versus intermediate-dose interferon-alpha-2b in patients with metastatic renal cell carcinoma. Cancer 2006;107(9):2254-61
10. Veronese FM, Pasut G. PEGylation, successful approach to drug delivery. Drug Discov Today 2005;10(21):1451-8
11. Glue P, Fang JW, Rouzier-Panis R, et al. Pegylated interferon-alpha2b: Pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group. Clin Pharmacol Ther 2000;68(5):556-67
12. Bukowski R, Ernstoff MS, Gore ME, et al. Pegylated interferon alfa-2b treatment for patients with solid tumors: A phase I/II study. J Clin Oncol 2002;20(18):3841-9
13. Daud AI, Xu C, HwuWJ, et al. Pharmacokinetic/pharmacodynamic analysis of adjuvant pegylated interferon alpha-2b in patients with resected high-risk melanoma. Cancer Chemother Pharmacol 2010;67(3):657-66
14. Xu C, Daud AI, DeConti RC, et al. Comparisons of pharmacokinetic profiles of high dose interferon-alpha2b (IFNalpha-2b) and peginterferon-alpha2b (PegIFNalpha-2b) in melanoma patients. Poster presented at the 38th Annual Meeting of the American College of Clinical Pharmacology; September 13 - 15; San Antonio, TX, USA; 2009
15. Eggermont AM, Suciu S, Santinami M, et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: Final results of EORTC 18991, a randomised phase III trial. Lancet 2008;372(9633):117-26
16. Grob JJ, Jouary T, Dreno RGB, et al. Adjuvant therapy with pegylated interferon alfa-2b (36 months) versus low-dose interferon alfa-2b (18 months) in melanoma patients without macro-metastatic nodes: eado trial. J Clin Oncol 2010;28 (18 Suppl):abstract LBA8506
17. Eggermont AM, Suciu A, Santinami M, et al. EORTC 18991 phase III trial: Long-term adjuvant pegylated interferon-alpha2b (PEG-IFN) versus observation in resected stage III melanoma: LONG-term results at 7.6-years follow-up. J Clin Oncol 2011;29(Suppl): Abstract 8506b
18. Schering-Plough Corp. Oncologic drugs advisory committee meeting briefing book: Pegintron (pegylated interferon alfa-2b) as adjuvant treatment of stage III melanoma 2009. Available from: Http://www.fda.gov/downloads/ AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ OncologicDrugsAdvisoryCommittee/UCM184002.pdf [Cited 12 July 2011]
19. Hauschild A, Weichenthal M, Rass K, et al. Efficacy of low-dose interferon {alpha}2a 18 versus 60 months of treatment in patients with primary melanoma of >= 1.5 mm tumor thickness: Results of a randomized phase III DeCOG trial. J Clin Oncol 2010;28(5):841-6
20. Hauschild A, Gogas H, Tarhini A, et al. Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: Expert opinion. Cancer 2008;112(5):982-94
21. Bottomley A, Coens C, Suciu S, et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: A phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group. J Clin Oncol 2009;27(18):2916-23
22. Dixon S, Walters SJ, Turner L, Hancock BW. Quality of life and cost-effectiveness of interferon-alpha in malignant melanoma: Results from randomised trial. Br J Cancer 2006;94(4):492-8
23. Cole BF, Gelber RD, Kirkwood JM, et al. Quality-of-lifeadjusted survival analysis of interferon alfa-2b adjuvant treatment of highrisk resected cutaneous melanoma: An Eastern Cooperative Oncology Group study. J Clin Oncol 1996;14(10):2666-73
24. Merck & Co., Inc. SYLATRON- (peginterferon alfa-2b) for injection, for subcutaneous use. 2001. Available from: Http://www.merck.com/product/usa/pi- circulars/s/sylatron/sylatron-pi.pdf [Cited 6 July 2011]
25. Dummer R, Mangana J. Long-term pegylated interferon-alpha and its potential in the treatment of melanoma. Biologics 2009;3:169-82
26. Merck & Co., Inc. Product information INTRON- A (interferon alfa-2b, recombinant for injection). 2008. Available from: Http://www.spfiles. com/piintrona.pdf [Cited 6 July 2011]